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PERSPECTIVE
Targeted therapy in acute myeloid leukemia: current status and new insights from a
proteomic perspective
Anneke D. van Dijka, Eveline S. J. M. de Bonta and Steven M. Kornblaub
aDivision of Pediatric Oncology/Hematology, Department of Pediatrics, University Medical Center Groningen, Groningen, the Netherlands;
bDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
ABSTRACT
Introduction: The biological heterogeneity of acute myeloid leukemia (AML) complicates personalized
medicine. Individual prognosis is typically based on the presence of chromosomal and genetic lesions.
Nevertheless, these classifications often lack a priori information about response to therapy. Since the
protein expression landscape reflects the functional activity state of cells, we hypothesize that analyzing
this can be used for the identification of protein activity markers to provide better risk stratification as
well as may provide targeted therapeutic guidance in AML.
Areas covered: Herein, we review recently new adopted drugs in the treatment for AML and discuss
how quantitative proteomic techniques may contribute to better therapeutic selection in AML.
Expert commentary: The net functional state of the cell is defined by the activity of protein within all
the pathways that are active in the cell. Recognition of the proteomic profile of the leukemic blast
could, therefore, complement current classification systems by providing a better a priori description of
what pathways are important within a cell as a guide to the selection of therapy for the patient.
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1. Acute myeloid leukemia
1.1. Introduction
Acute myeloid leukemia (AML) refers to the malignant clonal
evolution of hematopoietic stem cells in the bonemarrow affect-
ing normal blood formation. Although AML is relatively rare with
~20,000 new cases in the United States per year [1], without
treatment it is a rapidly fatal disease with median survival
between 10 and 15 months [2]. Over the past 50 years, due to
significant improvements in chemotherapeutic strategies, hema-
topoietic stem cell transplantations (HSCT) and supportive care,
AML outcome has slowly improved and currently 70% of pedia-
tric patients, 35–40% of adults younger than 60, and 5–15% of
the elderly (>60 years) can be cured [2–4]. These numbers are
obviously still unsatisfying and underline the need to investigate
treatment opportunities beyond the existing.
In this review, we will first discuss currently used therapeutic
approaches in AML, including targeted treatment strategies that
have recently entered the clinic. Then, we will introduce the
general concept of quantitative proteomics and debate why
we think this technology may hold promise in identifying new
diagnostic and prognostic biomarkers and in providing new
therapeutic leads, especially in a heterogeneous disease as AML.
1.2. Current treatment strategies in AML
Current treatment approaches in AML focus on resetting the
bone marrow with the essential goal of eradicating the malig-
nant leukemic clone and restoring normal blood production.
Standard therapy involves one or two cycles of conventional
induction chemotherapy based on cytarabine and an anthracy-
cline in adults, i.e. 3 days anthracycline followed by 7 days
cytarabine intravenously (‘3 + 7’), and with the addition of etopo-
side as the third drug in the pediatric population. These regimes
result in complete remission (CR) in 85–90% of treated children,
60–80% of adults <60 years and in 40–60% of adults >60 years
[2,3,5]. More recently the recognition of some commonly occur-
ringmutations and the development of newer agents that target
the mutated proteins arising from these affected genes has led
to the incorporation of those agents into induction regimens
which will be further discussed in paragraph 1.3. Induction ther-
apy is followed by several, typically 3–6, courses of consolidation
to minimize the risk of relapse. The choice of post-remission
consolidation depends on the response to induction therapy
and the presence of molecular genetic and cytogenetic abnorm-
alities (Table 1, modified from the European LeukemiaNet (ELN)
risk stratification by genetics for adults [5] and genetically
defined prognostic groups in pediatric AML [6]). For example,
favorable risk group patients are often treated with a high dose
of cytosine arabinoside post-remission and patients with a more
unfavorable cytogenetic profile are more typically referred for
HSCT in the first remission.
1.3. Targeted therapeutic approaches in AML
1.3.1. Targeted drugs for subsets mutated AML
Cytogenetic status is often considered as the most significant
prognostic factor in AML. However, some leukemias (about
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25% of pediatric and almost 50% of adult AML cases) have
normal cytogenetics (CN-AML) and outcomes within this
group are highly variable. Risk stratification and treatment
choice in this group often depend on the presence of one or
more driver mutations [2,3]. On average, an adult AML patient
has 13 mutations including 2–4 driver mutations, some of
which already listed in Table 1 [7,8]. The majority of these
mutated genes are not targetable themselves and only serve
as a prognostic factor, but there are a few noteworthy
exceptions.
Mutations in the FMS-like tyrosine kinase 3 (FLT3) are found
in ~30% of AML patients and yield poor prognostic signifi-
cance at all ages since these patients often experience relapse
after obtained CR [9,10]. Recently midostaurin and gilteritinib,
which target the activating FLT3 mutated receptor regardless
of mutation status, have been developed and have received
FDA approval [11]. The kinase inhibitor midostaurin, first
synthesized in 1986, was initially developed to target protein
kinase C (PKC) and vascular endothelial growth factor receptor
(VEGFR), but limited efficiency was found based on clinical
trials in various diseases. It was recognized later that midos-
taurin inhibits FLT3 and KIT tyrosine kinases and was consid-
ered as a treatment for FLT3 mutated AML [12].
Another frequently occurring and targetablemutation in AML
is the IDH mutation. An IDH1 or IDH2 mutation happens in
15–20% of newly diagnosed AML patients, most commonly in
the normal karyotype-classified cases. Mutant forms are asso-
ciated with abnormal enzymatic activity that results in the pro-
duction of an atypical metabolite (2-hydroxyglutarate, "2-HG")
which poisons TET2 leading to epigenetic dysregulation and
a hematopoietic differentiation block at an early stage in the
AML development [13,14]. Small molecule inhibitors have shown
to reverse these effects and in 2017 the first IDH2 inhibitor
(enasidenib) received FDA approval for the treatment of relapsed
or refractory adult AML patients with the IDH2mutation [15]. This
was followed by approval of the IDH1 inhibitor ivosidenib in
2018 [16].
1.3.2. AML-based immunotherapy
In hematological diseases, significant improvement in outcomes
has been shown with immunotherapy-based regimes. The first
FDA approved antibody-based drug in cancer was rituximab,
which targets the antigen CD20 on the surface of specific B-cell
non-Hodgkin lymphoma (NHL) cells and is part of the gold
standard ever since [16,17]. Moreover, in B-cell acute lymphoid
leukemia (B-ALL), success has been booked with chimeric anti-
gen receptor (CAR)-T-cell therapy. CAR-T-cells are genetically
engineered patient cells that express CARs to target specific
antigens on cancer cells. Tisagenlecleucel targeting the CD19
antigen was the first CAR-T cell drug that received FDA approval.
In 2018, Maude et al. published their phase II study of
Tisagenlecleucel in pediatric B-ALL that showed a complete
remission rate of 81% [18]. The relapse rate, however, remained
high, especially with antigen-negative leukemia [19]. The key to
success in immunotherapy lies within the identification of
a target antigen that is predominantly expressed on the surface
of malignant cells, such as CD20 on B-cell NHL and CD19 on
B-ALL cells. Expression of such target should preferably be
restricted to malignant cells, and expression should be present
onmature malignant cells as well as on malignant stem cells. For
AML the identification of leukemia-specific antigens has been
less successful and current therapeutic antibody and CAR-T
approaches are directed against CD33 and CD123, both of
which are also present on normal hematopoietic stem cells;
thus caution in their usage is warranted [20].
Gemtuzumab ozogamicin (GO) is a drug that targets the
CD33 transmembrane protein and has been approved for
Table 1. AML risk classification by genetics.
Risk Molecular abnormality
Favorable t(8;21)(q22;q22); RUNX1-RUNX1T1
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB;MYH11
t(15;17)(q22;q21)/PML-RARA
t(1;11)(q21;q23)/MLL-MLLT11(AF1Q)
Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow*
Biallelic mutated CEBPA
Intermediate Mutated NPM1 and FLT3-ITDhigh*
Wildtype NPM1 without FLT3-ITD or with FLT3-ITDlow*
t(9;11)(p22;q23); MLLT3-KMT2A














Complex** or monosomal karyotype




*FLT3-ITDlow; low allelic ratio (<0.5), FLT3-ITDhigh; high allelic ratio (>0.5).
**Presence of more than or equal to 3 or more chromosomal aberrations in the
absence of a WHO-designated recurring translocation or inversion [5].
***Adverse prognostic risk in the absence of favorable risk molecular
abnormality.
Article Highlights
● AML is a very aggressive disease that occurs across all ages, and
although survival is markedly better in the pediatric population, it
remains a leading cause of childhood and adult cancer death.
● For existing therapeutic strategies in AML, there is a lack of markers
that are capable of reliably predicting prognosis or the therapeutic
response prior to treatment.
● Strategies that are capable of integrating the net effect of all pathways
on the entire spectrum of downstream protein effectors and actuators
would provide a more complete systems biology view of the function
of the leukemic cell.
● Despite the chaos of all the combinations of genetic events that occur
in AML, a finite number of recurrent protein expression signatures
exist. These proteomic profiles correlate with response to treatment
and prognosis, and can be independent of cytogenetic or molecular
status.
● Assessment of a broad spectrum of the proteome could suggest
logical points for combination targeted therapy in AML.
● Knowledge of a patient’s proteomic signature membership only has
utility if a reliable knowledge based on which targeted agent should
be used in each signature is available.
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relapsed AML after a promising phase II trial in 2000. Ten years
later GO was voluntarily withdrawn when results from
a randomized trial did not show improved efficacy between
treatment arms. However, in this study, patients received
lower dose chemotherapy when GO was added to their treat-
ment compared to patients who only received chemotherapy.
Subsequent studies have shown the efficacy of adding GO to
chemotherapy leading to its reapproval in 2017 [21,22].
1.3.3. Targeting signaling pathways in AML
The inhibition of a single protein in clinical practice with regards to
AML has been very limited, until last year. In November 2018, the
BCL-2 inhibitor venetoclax (ABT-199) was approved in combina-
tion with azacytidine, decitabine, or cytarabine for the treatment
of newly diagnosed AML patients 1) older than 75 years or 2) with
comorbidities that excluded them from induction therapy. BCL-2
is an apoptotic enzyme that prevents cell death by regulating the
intrinsic apoptotic, so-calledmitochondrial pathway. Via this path-
way, apoptosis depends on the activation of caspases via mito-
chondrial outer membrane permeabilization (MOMP). BCL-2
prevents the MOMP and apoptosis by binding and sequestering
effector pro-apoptotic proteins such as BIM, PUMA, BAD, BID, and
BIK [23]. Since BCL-2 was recognized as protein to prevent cell
death, it became an interesting target in cancer. BCL-2 expression
was first found in lymphoid cells and therefore studies began to
investigate the potential of targeting BCL-2 in chronic lymphoid
leukemia (CLL) and lymphomas, resulting in the first FDA approval
for venetoclax in 2016 for CLL [23]. Venetoclax as monotherapy
showed biological activity in AML patients as well, but responses
remained limited. Resistance and disease progression can be
acquired via the upregulation of alternative anti-apoptotic pro-
teins, such as MCL-1, that also could bind the effectors. And since,
it is not the expression quantity that sensitizes cells after BCL-2
inhibition but rather the amount of protein that is bound to the
pro-apoptotic effectors that driveMOMP [24]. A breakthroughwas
achieved when the BCL-2 inhibitor was combined with the hypo-
methylating agent 5-azacitidine. Complete remission rates for
patients treated with the combination were 67% compared to
earlier described 28%when treatedwith a hypomethylation agent
only. Moreover, the combination improved overall survival to
a median of 17.5 months compared to 10.4 months in 5-azaciti-
dinemonotherapy [25]. Similar clinical results were achievedwhen
venetoclax was combined with low-dose cytarabine [26,27].
Despite the success of venetoclax, targeting single proteins is
often not sufficient to kill the leukemic cell as they can bypass the
inhibition by alternative escape routes [28]. Targeting these
routes is often performed by combining available drugs to target
multiple proteins of the intracellular signaling pathway or by
targeting the upstream trigger that activates the pathway. For
example, patients with chronic myeloid leukemia (CML) express
the fusion protein BCR-ABL1 due to the chromosomal
Philadelphia translocation. The discovery of a drug (imatinib)
that targets the kinase activity of BCR-ABL1, thereby preventing
the downstream activation of the proteins that actuate the
leukemic physiology, improved 10 years overall survival of CML
to 83% [29]. AML holds a more complex etiology. In AML it is not
one but multiple signal transduction pathways that are recog-
nized to promote leukemogenesis and affect proliferation and
cell survival [30]. The idea that simultaneous activation of various
signaling pathways influence outcome and response to therapy
in AML has been studied extensively and has led to the devel-
opment of numerous agents that target components of acti-
vated signaling pathways. The mitogen-activated protein
kinase (MAPK)/extracellular-regulated kinase (ERK) is an example
of a frequently dysregulated pathway in AML. Inhibitors against
compounds of this pathway have been developed and trials with
MEK inhibitors are underway. Although the use of MEK inhibitors
has been reported as safe and tolerable, limited efficiency was
recently observed in a phase 2 clinical trial [31]. It is likely that
only therapeutics that target multiple activated signaling path-
ways will be beneficial for patients with AML.
Another pathway that is aberrantly upregulated in myeloid
leukemia is the hedgehog signaling pathway. Normally, the
hedgehog pathway is activated during embryogenesis and
silenced after birth [32]. The intracellular hedgehog pathway is
activated upon stimulation of an integral membrane protein
Smoothened (SMO). If activated, SMO triggers translocation of
the glioma-associated proteins (GLI) to the nucleus which will
result in target gene transcription. Both overexpression of SMO
and GLI are associated with resistance to therapy and hedgehog
pathway inhibition indeed increases drug sensitivity in AML [33].
These findings prompted doctors to combine pharmacological
inhibition of the hedgehog pathway with chemotherapy in the
clinical setting. The SMO inhibitor glasdegib (PF-04449913) pre-
vents downstream activation of the hedgehog pathway and was
well tolerated and safe when combined with chemotherapy,
including low-dose cytarabine and decitabine, in AML and MDS
patients in a phase I clinical trial [34]. Promising results from
a phase II study were recently published where glasdegib com-
bined with low-dose cytarabine significantly improved overall
survival and complete remission rates in adult AML and MDS
patients who were ineligible for high-dose chemotherapy com-
pared to who only received low-dose cytarabine [35]. Notably,
improvement of outcomes with the combination therapy was
independent of cytogenetic group or mutational status in this
phase II study. The use of glasdegib in combination with high-
dose chemotherapy or azacytidine is currently under investiga-
tion in a multicenter phase III clinical trial (ClinicalTrials.gov,
NCT03416179) for previously untreated AML patients.
An overview of the above discussed therapeutic targets that
recently have been approved for subgroups of AML is shown in
Table 2. The integration of these compounds as optional treat-
ments is a major breakthrough for AML, especially for those with
very poor prognosis (relapsed and refractory AML) and the
elderly. Many more clinical trials are currently ongoing testing
different combinations of therapeutic possibilities for different
subtypes of patients at different stages of disease.
2. Utilizing proteomics in AML
2.1. Why should we use proteomics in AML?
The aforementioned, current risk classification in AML is based on
the presence of chromosomal abnormalities and recurrent driver
mutations in the leukemic cell. Both classifications yield great
prognostic relevance and have contributed to disease classifica-
tion and risk stratification [7]. However, chromosomal and mole-
cular abnormalities are difficult to treat themselves. Of note is
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that the majority of drugs against genes that are frequently
mutated in AML target all forms of the target proteins and are
not specific for inhibiting themutated form (e.g. midostaurin and
gilteritinib in FLT3), with drugs targeting the IDH mutations as
notable exception. Many developed drug target proteins that are
not mutated in AML, but which are functionally ‘downstream’ of
mutated genes. Moreover, leukemic blasts are affected by exter-
nal and environmental factors including cytokine exposure,
hypoxia, and mesenchymal stromal cell (MSC) interaction and it
is believed that the combination of the (epi)genetic changes and
microenvironmental influences determines leukemic cell fate.
The net effect of these combined influences is predominantly
displaced on the protein level and their affected signaling path-
ways [42]. We, therefore, argue that characterization of differen-
tially expressed proteins and recognition of proteomic signatures
within (subgroups of) AML may facilitate and improve treatment
stratification.
Multiple signaling transduction pathways are involved in
the development and progression of AML. While these path-
ways are typically studied independent of each other, they
actually interact with each other to direct the happening of
the leukemic cell. Strategies that simultaneously look at all
of these pathways, and that are capable of integrating the
net effect of all pathways on the entire spectrum of down-
stream protein effectors and actuators would provide a more
complete ‘systems biology' view of the function of the leu-
kemic cell. Crucial to the improving success of cancer ther-
apy has been the realization that combination therapy is
typically required to improve outcome. An approach that
simultaneously assesses the activity of multiple pathways
and multiple effectors could suggest logical points for com-
bination targeted therapy. To achieve this, assessment of
a broad spectrum of the proteome is required. The two
main techniques that are capable of analyzing the proteome
in AML are mass-spectrometry (MS)- and antibody-based
techniques.
2.2. High-throughput proteomic techniques used in AML
2.2.1. Mass spectrometry
based proteomics is a well-established technique and commonly
used for identification and quantitative assessment of proteins
within complex samples. MS is based on the measurement of
charged ions from a protein analyte. To increase the sensitivity of
the measurement, different compounds in very complex sam-
ples can be separated by gel electrophoresis, liquid chromato-
graphy (LC-MS), gas chromatography (GC-MS), or another mass
spectrometer (MS-MS) prior to analysis. Historically, there are two
ways to detect proteins by MS including using a ‘top-down’ or
‘bottom-up’ approach [43,44]. After protein extraction, the top-
down approach separates and quantitates purified intact pro-
teins (ions) using 2D gel electrophoresis or MS-MS and enables
the characterization of unique proteoforms including degrada-
tion products, protein isoforms, post-translational modifications
(PTMs), as well as low-mass proteins. The usage of the top-down
approach is however often limited to low-throughput individual
protein studies. In contrast, the bottom-up approach is more
broadly used for analyzing more complex protein mixtures.
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proteomics’ [45]. With this technique, the proteins are digested
into peptides by enzymes (e.g. trypsin) before analysis by MS.
Since only one fraction of all produced peptides (ions) is restored
into a protein, PTMs and alternative isoform information will not
be recovered in bottom-up proteomics. Both approaches are
thus associated with advantages and disadvantages and choice
of technique depends on the research aim of the study.
In both approaches, before MS analysis, ionization of the sam-
ple is performed to break molecules into charged ions. These ions
then pass through an electric or magnetic field which sorts them
based on mass-to-charge (m/z) ratio. Relative abundance of the
separated ions is oftenpresented in amass spectrum todecipherer
the identity of the proteins. The most frequently used techniques
for ionization of analytes are ‘matrix-assisted laser desorption/
ionization’ (MALDI) or electrospray ionization (ESI). Using MALDI,
an energy-absorbing-matrix is added to the analyte and when the
sample is irradiated with laser energy, the matrix will ionize the
analyte [46]. MALDI usually produces single-charged ions (z = 1)
with a maximummass of 350 kDa. The ion sorting process accord-
ing to the mass-to-charge ratio is then often performed by a ‘time
of flight’ (TOF) analyzer. This technique simply measures the travel
time of the ion before it reaches the detector [47]. The lighter the
ion, the faster and vice versa. A variation of MALDI is ‘surface-
enhanced laser desorption/ionization’ (SELDI) [48]. With this tech-
nique, proteins are not bound to species in the matrix but to the
surface. Another technique to ionize an analyte is with ESI. The
protein analyte is dissolved in a conductive solvent and high
voltage is then applied to the sample to create aerosols. While
MALDI produces single-charged ions, ESI can produce multi-
charged ions (up to ~75) and can be applied to in particular
proteins with high molecular masses [49].
The clinical applications of MS in acute leukemia include
the identification of diagnostic biomarkers. Xu et al. for exam-
ple developed a proteomic-classification system by analyzing
151 de novo acute leukemia patients using SELDI-TOF MS. The
proteomic-subtypes correlated with the type of leukemia
(acute promyelocytic leukemia (APL), granulocytic AML, mono-
cytic AML, and acute lymphocytic leukemia (ALL)). The authors
suggest that this proteomic classification holds promise to
identify potential protein biomarkers for each specific sub-
group of acute leukemia [50]. Protein biomarkers are also
identified to distinguish between malignant AML and the
premalignant myelodysplastic syndrome (MDS). Clinically,
measurement of the percentage of bone marrow blasts
remains the method of monitoring disease progression.
A patient is diagnosed with MDS if the bone marrow contains
<20% blasts, but the diagnosis changes into AML if 21% or
more blasts are found. It is however clear that this cutoff
between premalignant to malignant disease does not pre-
cisely reflect the degree of malignancy. It would be of clinical
interest if a reliable biomarker could predict which MDS
patients have a higher chance to progress into AML. Using
MS, serum protein CXC chemokine ligands 4 and 7 (CXCL4,
CXCL7) have been identified as proteins with decreased
expression in advanced MDS [51]. Another study using MALDI-
TOF MS identified that MOES, EZRI, and AIFM1 could be con-
sidered as AML-specific expressing proteins and therefore may
serve as diagnostic biomarkers to distinguish MDS and
AML [52].
MS has also been used to identify prognostic biomarkers in
AML. SELDI-TOF MS analysis of 54 samples from newly diagnosed
AML patients revealed two prognostically different protein pro-
files. The authors identified a marker with high discriminative
potential that predicted poor survival independent from cytoge-
netics in ~70%. MS peptide sequencing could identify the marker
as the mature granulocyte marker S100A8. Additional Western
blot analysis could confirm that S100A8 at the time of diagnoses
was highest expressed in patients with a poor prognosis [53].
Another member of the S100 family with prognostic value in
AML was recently discovered by Alanazi et al. Using LC-MS/MS,
110 aberrant expressed nuclear proteins were identified in AML
patients compared to normal CD34+ cells. S100A4 was the highest
overexpressed protein and additional research showed that its
expression is required for blast cell survival but not for normal
cell development suggesting this could be a new therapeutic
target [54].
The prognostic significance of driver mutations in AML
often depends on co-occurring circumstances. For example,
the impact of an IDH mutation itself remains controversial [55].
It became however clear that the level of the produced onco-
metabolite 2-HG actually has prognostic value. Measurement
of the 2-HG levels with reverse-phase LC-MS in 223 de novo
AML samples showed that patients with 2-HG levels above 700
ng/ml were highly susceptible to have an IDH mutation
(~87%). Pretreatment levels were not predictive for outcomes,
but 2-HG levels >200 ng/ml after achieving CR predicted
worse overall survival in this population [56]. In line with
these findings, Janin et al. published that low 2-HG serum
levels after induction therapy indeed correlated with a better
outcome in terms of overall and disease-free survival [57].
Although many targets have been identified, AML is known
as a phenotypically and functionally distinct disease and intra-
tumor heterogeneity is one reason that may delay the transla-
tion of these targets to the clinic. A better understanding of
the intratumor heterogeneity of leukemic blasts might
improve this process. Combining MS and flow cytometry
(mass cytometry or cytometry by time-of-flight, ‘CyTOF’)
enables measurement of protein levels in single cells including
PTMs and proteolysis products [58]. Levine et al. have used
this technique in 16 pediatric AML patients to analyze surface
and intracellular signaling protein levels in millions of leukemic
and nonmalignant cells. It is remarkable that the authors report
substantial decoupled profiles between surface markers and
intracellular proteins suggesting that not all surface markers
necessarily reflect the intracellular protein expression state [59].
2.2.2. Antibody-based protein microarrays
One other approach that enables us to detect and to quantify
proteins is by the use of antibodies. The advantage of anti-
body-based proteomic techniques is that antibodies against
whole proteins as well as against their isoforms (e.g. alterna-
tive splicing variants, PTMs) can be used. Among antibody-
based techniques, the protein microarray is frequently the
technique of choice to study proteomics in leukemia.
Functional protein microarrays are generally used in basic
research laboratories to investigate the biochemical activities
of proteins such as their interactions with other proteins, DNA,
RNA, small molecules, and lipids. Discussing the applications
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of these arrays in leukemia is however beyond the scope of
this manuscript.
For clinical purposes, analytical protein microarrays have
been used for large-scale protein expression profiling as well
as for biomarker discovery. The main two types of analytical
protein microarrays are the forward-phase protein array (FPPA)
and the reverse-phase protein array (RPPA). In FPPA, multiple
solid-phased antibodies are printed on an array with known
positions. A patient protein lysate can then be printed on the
array and will bind to the particular antibody if the protein is
expressed. After exposure to a secondary antibody, protein
expressions are measured. The advantage of this technique
is that expressions of multiple proteins are measured simulta-
neously per sample [60]. However, finding two highly specific,
non-overlapping antibodies complicates the generalized
usage of this technique. Another disadvantage of FPPA is
that a relatively high amount of protein lysate is needed for
analysis, which is certainly not always available in the clinical
setting.
Both limitations can be overcome by RPPA. With RPPA,
a significantly lower amount of protein lysate is needed and
instead of antibodies, protein lysates of multiple samples are
printed onto a slide. The expression of a single protein is then
measured simultaneously in all samples by antibody detection.
RPPA is unique as it can assess protein expression levels includ-
ing PTMs in >1000 (patient) samples at the same time. The
limitation of this technique compared to MS-based techniques
is that only strictly validated antibodies can be used, as it is
crucial to minimize nonspecific binding on the array to prevent
false-positive protein expressions. Antibody-based arrays, there-
fore, limit the coverage of the proteome and lack the ability to
identify de novo proteins that are expressed. However, on the
other hand, if validated, measured expression of the protein of
interest and PTMs are highly accurate and sensitive. We and
others have shown the high inter- and intra-slide reproducibility,
precision, throughput, and reliability of RPPA [61,62]. In hemato-
logical malignancies, these arrays have been generated for adult
and pediatric AML [42,63], APL [64], adult and pediatric ALL [65],
and AML derived MSC [66] and a CLL array is underway.
Since RPPA measures protein expression in multiple samples
at the same time, this technique can be used to identify proteins
that are differentially expressed in leukemia compared to protein
expression in nonmalignant bone marrow and blood cells.
Abnormal high or low expression of a protein of interest could
potentially be considered as diagnostic biomarker which may be
useful in early disease detection. Recognition of specific protein
expression patterns could furthermore improve subcategoriza-
tion within the heterogeneous landscape of AML. Kornblau et al.
have shown distinct proteomic profiles across FAB defined mor-
phological categories within 256 adult AML patients using RPPA.
There were 24 proteins out of 51 tested that were distinctly
expressed between myeloid (M0-M2) or monocytic (M4-M5)
AML. Patients in M0-M5, in addition, had a different proteomic
profile than M6 and M7 categorized patients. In addition, two
individual proteins, TP53 and BAX, showed different expressions
across different cytogenetic abnormalities. Protein expression
also correlated with mutational status. FLT3 mutated patients
had a higher expression of 13 proteins, including phosphorylated
STAT5 and PKCα. Interestingly, these findings were in line with
previously higher described higher mRNA expression of these
proteins in FLT3-AML [62].
RPPA-based proteomic profiles to distinguish between dif-
ferent leukemic subtypes are also defined. Hoff et al. identified
different protein expression signatures between AML and ALL
[63,65], as well as between AML and APL [64]. Interestingly,
comparable protein profiles between pediatric AML and ALL
patients were also defined. For example, one protein constel-
lation with both AML as ALL patients showed upregulation of
SMAD proteins as well as proteins acting in the mTOR signal-
ing pathway. Therapeutic targets against these proteins could
potentially be effective in both leukemias with this protein
profile. The patients did not share clinical features or demo-
graphics suggesting that protein patterns are not driven by
genetic events only [65].
Besides the identification of diagnostic markers within and
between specific types of leukemia, RPPA provides a platform
to identify prognostic biomarkers that predict outcome in
(subgroups of) AML.
For instance, Quintas-Cardama et al. investigated TRIM62
levels in adult AML patients and were the first to describe
a tumor suppressor role for TRIM62 in AML [67]. Low TRIM62
protein expression was identified as an adverse prognostic
factor for survival and complete remission in this population
which was supported by higher white blood count and higher
levels of bone marrow blasts and monocytes. The loss of
TRIM62 was prominent in normal karyotype AML and the
prognostic significance was notably independent of NPM1 or
FLT3 mutation. Since current post-remission treatment strati-
fication in normal karyotype depends on NPM1 and FLT3
status, this report highlights the relevance of analyzing the
proteome to further refine treatment stratification.
While studying the same population, high phosphorylation
of serine 318–321 on FOXO3 was identified as an independent
adverse prognostic factor [68] and low expression of ASH2L
was related to poorer outcomes as well [69]. Other individual
prognostic protein biomarkers that have been discovered in
AML include LGALS3 [70], TGM2 [71], and FLI1 [72].
2.3. Translation to the clinic
2.3.1. Prediction of therapy sensitivity
In this manuscript, some identified protein activity biomarkers in
diagnostics and prognosis in AML have been described.
Although the impact of these markers on outcome can be
clear, the translation of protein activity markers to the clinic
remains relatively limited. One reason being that they do not
impact the choice of treatment. In a malignant disease such as
AML characterized by a chaos of combination of genetic events,
doctors rather overtreat a patient instead of using a prognostic
marker with not completely perfect prediction [73]. However,
since a finite number of recurrent protein expression signatures
exist, we argue that these patterns surely suggest targets to aim
for targeted therapy. A vast and growing list of inhibitors against
proteins is available and identification of clinical scenarios in
which these inhibitors may be more sensitive may help bring
highly predictive and validated protein markers to the clinic.
6 A. D. VAN DIJK ET AL.
Proteomic profiling can assist in identifying situations in which
specific protein inhibitors may be more sensitive.
For example, a variation of BET inhibitors is currently under
investigation in clinical trials in AML. In leukemia, inhibition of
the BET-member bromodomain containing 4 (BRD4) prevents
transcription of oncogenic genes (e.g. MYC) through inhibiting
BRD4 protein binding to acetylated lysine residues of histone
tails [74,75]. Interestingly, this discovery was based on an RNA
interference screening, and although leukemic cells are more
sensitive to BRD4 inhibition than normal hematopoietic cells,
the impact of BRD4 mutations or aberrant protein expression
remained unknown for many years. In 2017, our group ana-
lyzed and reported BRD4 protein expression in AML using
RPPA from 511 newly diagnosed adult AML patients [76].
Patients who expressed higher BRD4 protein levels compared
to normal, nonmalignant, bone marrow-derived CD34+ cells
had inferior remission durations and overall survival. These
analyses retained statistical significance in patients with unfa-
vorable cytogenetics. The adverse prognostic impact of high
BRD4 expression was again observed when the analysis was
restricted to only the freshly prepared samples (upon arrival in
the laboratory, n = 205/511) with a median survival of 103 vs.
53 weeks (P = 0.04). Median event-free survival was also sig-
nificantly shorter for high BRD4 expressors (58 vs. 87 weeks, P
= 0.02). In line with these findings, high classified BRD4 expres-
sors had a higher percentage of bone marrow blasts (67% vs.
51%, P < 0.001) and peripheral blood blasts (51% vs. 33%, P <
0.001). Morphologically, high BRD4 expressors had more often
undifferentiated (M0) or minimal maturation (M1) AML as
defined by the FAB classification compared to low-classified
patients (26% of high vs. 7% of low BRD4 expressors). If BRD4
is higher expressed in undifferentiated and minimal matura-
tion AML, then these patients, in particular, may potentially
benefit from the addition of BET inhibitors to their therapeutic
regime. If we could develop a test that measures BRD4 expres-
sion in a fast, sensitive, and clinical-applicable approach, we
can easily select patients that may be the ultimate candidates
for BET inhibitors.
2.3.2. Clinical-applicable tools to predict protein inhibitor
sensitivity
Techniques that rapidly provide information about relative
protein expressions are enzyme-linked immunosorbent assay
(ELISA) and immunohistochemistry (IHC). The advantage of
ELISA above IHC is that quantification along all concentrations
is possible while in IHC signal saturates and accurate quanti-
fication is limited [77]. On the other hand, a disadvantage of
ELISA is that a larger amount of protein lysate is needed which
is not always available in the clinical setting. Another option to
measure direct protein expression when a patient enters the
clinic is the usage of FPPA. As discussed earlier, this technique
allows the detection of multiple proteins in a single protein
sample. We, therefore, believe that FPPA has the potential to
become an important diagnostic tool in the clinical setting of
AML. In the end, it is not the single protein expression, but the
entire proteomic network that determines the net effect of the
leukemic cell. Identification of sets of proteins instead of indi-
vidual proteins that correlate with clinical characteristics in
AML is still in its infancy but truly holds promise to bring
personalized medicine and management to the next level.
A schematic overview of how high-throughput proteomics
could lead to specific pharmacological treatment for
a subgroup of patients and how this could be used to
a more personalized medicine approach is shown in Figure 1.
3. Future applications
3.1. RPPA analysis in multicenter clinical trials
The big advantage of RPPA over other proteomic techniques is
that it is very sample sparing, requiring only 3 × 105 cells to
analyze the expression of ~400 proteins. This makes RPPA
a suitable approach for clinical applications. All protein samples
are exposed to the same antibody at once allowing direct com-
parison of protein expression across the dataset. Therefore, we
are currently exploring the usage of RPPA in multicenter clinical
trials. Excitingly, patient samples can be obtained before and
after treatment, and changes in protein expression over time
can be analyzed by RPPA when samples are printed on the
same slide. We hypothesize that changes in specific proteins
may correlate with the resistance or sensitivity to certain treat-
ment approaches retrospectively. Identification of these protein
patterns may contribute to our understanding of the mechanism
that drives chemoresistance. If we, for instance, could identify
significant changes in protein expression upon 24 h after treat-
ment that correlate with relapse at the long term, we may block
that defensive adaptation by anticipate the changes and incor-
porating a specific inhibitor for that protein, or by early selecting
of patients that may benefit frommore intensive treatment regi-
mens such as allogeneic HSCT.
3.2. Conclusion
For existing therapeutic strategies in AML, there is a lack of
markers that are capable of reliably predicting prognosis or
the therapeutic response prior to treatment. There is hope that
elucidation of the AML-specific proteome will prompt the dis-
covery of novel therapeutic targets and biomarkers. The big,
unexpected success of BCL-2 protein inhibition in AML by vene-
toclax illustrates the potential impact of inhibition of key com-
ponents of the proteome which encourages us to accelerate
translation of validated proteins as diagnostic, prognostic, and/
or therapeutic biomarker to the clinical setting. The develop-
ment of an applicable clinical test that quickly provides informa-
tion about relative protein expression of the patient may
contribute to better stratification and eventually may be the
next step in predictive and personalized medicine.
4. Expert commentary
AML is a complex disease and choosing the best treatment
option for individual patients is an everyday challenge for hema-
tologists. Patients are generally well characterized for the mole-
cular events, translocations, and mutations that define their
leukemia, but there is a disconnect between this information
and the clinic as most of these cannot currently be targeted.
Furthermore, these events occur in a nearly infinite number of
combinations and the net effect of these changes on the
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physiology of the cell cannot easily be predicted just from the
knowledge of which event is present. Concurrent with the explo-
sion in genetic characterization, there is simultaneously an explo-
sion in new therapeutic agents targeting specific critical
components of various pathways affecting all components of
the cell metabolism and physiology. These combined genetic
events have a summary effect on the cell through the down-
stream effects they have. It may, therefore, be possible to use
targeted agents aimed at a downstream consequence of
a mutated gene, to interfere with that genes' ability to drive
leukemia, even if the actual mutated protein cannot be targeted.
As clinicians, we need a means to determine which targeted
agent would have a beneficial effect in which situation. Since
the net ‘summary’ functional state of the cell is defined by the
activity of proteins within all the pathways that are active in the
cell, we argue that recognition of which proteins and pathways is
being utilized can provide this missing link between specific
mutations, alone or in combination and the panoply of available
targeted therapeutics. The recognition of the proteomic profile
of the leukemic blast could, therefore, complement current clas-
sification systems by providing a better a priori description of
what pathways are important within a cell as a guide to the
selection of therapy for the patient. We and others have estab-
lished that despite the chaos of all the combinations of genetic
events that occur in leukemia, a finite number of recurrent
protein expression signatures exist in leukemia and that these
proteomic profiles correlate with response to treatment and that
this can be independent of cytogenetic or molecular status.
Additionally, these patterns suggest targets to aim for with
targeted therapy.
The biggest remaining challenges to the routine clinical use
of these are means of defining these patterns and verification
of the predictive guidance they might provide toward therapy
selection. Current platforms utilize methodologies appropriate
to the research laboratory but not to the routine clinical
molecular laboratory. Developing the means of rapidly per-
forming tests that enable classification of the protein signature
membership, which can be Clinical Laboratory Improvement
Amendments (CLIA) certified, and therefore can be broadly
utilized is half of the need. Performing validation studies that
confirm that suggestions of which targeted agents would
increase therapeutic efficacy when used in a particular signa-
ture is the other half. Knowledge of signature membership
only has utility if a reliable knowledge based on which tar-
geted agent should be used in each signature is available.
Another weakness is that studies have looked at a finite por-
tion of the proteome and there may be many other clinically
relevant and targetable proteins that have not been recog-
nized. Furthermore, as new agents that are not currently
covered by the proteomic analyses performed to date are
developed, there must be ways to incorporate that growing
list of available targeted agents. The ability of these signatures
to evolve as new drugs and targets are identified, studied and
their relevance determined is required.
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